400 related articles for article (PubMed ID: 24905066)
1. Genetic predictors of long-term response to growth hormone (GH) therapy in children with GH deficiency and Turner syndrome: the influence of a SOCS2 polymorphism.
Braz AF; Costalonga EF; Trarbach EB; Scalco RC; Malaquias AC; Guerra-Junior G; Antonini SR; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1808-13. PubMed ID: 24905066
[TBL] [Abstract][Full Text] [Related]
2. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome.
Braz AF; Costalonga EF; Montenegro LR; Trarbach EB; Antonini SR; Malaquias AC; Ramos ES; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433
[TBL] [Abstract][Full Text] [Related]
3. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.
Costalonga EF; Antonini SR; Guerra G; Coletta RR; Franca MM; Braz AF; Mendonca BB; Arnhold IJ; Jorge AA
Pharmacogenomics J; 2012 Oct; 12(5):439-45. PubMed ID: 21468024
[TBL] [Abstract][Full Text] [Related]
5. The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency.
Costalonga EF; Antonini SR; Guerra-Junior G; Mendonca BB; Arnhold IJ; Jorge AA
J Clin Endocrinol Metab; 2009 Feb; 94(2):588-95. PubMed ID: 18984657
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency.
Jorge AA; Marchisotti FG; Montenegro LR; Carvalho LR; Mendonca BB; Arnhold IJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1076-80. PubMed ID: 16291702
[TBL] [Abstract][Full Text] [Related]
7. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
[TBL] [Abstract][Full Text] [Related]
8. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
[TBL] [Abstract][Full Text] [Related]
9. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children.
Pilotta A; Mella P; Filisetti M; Felappi B; Prandi E; Parrinello G; Notarangelo LD; Buzi F
J Clin Endocrinol Metab; 2006 Mar; 91(3):1178-80. PubMed ID: 16394090
[TBL] [Abstract][Full Text] [Related]
10. Growth Hormone (GH) receptor C.1319 G>T polymorphism, but not exon 3 retention or deletion is associated with better first-year growth response to GH therapy in patients with GH deficiency.
Wan L; Chen WC; Tsai Y; Kao YT; Hsieh YY; Lee CC; Tsai CH; Chen CP; Tsai FJ
Pediatr Res; 2007 Dec; 62(6):735-40. PubMed ID: 17957148
[TBL] [Abstract][Full Text] [Related]
11. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
[TBL] [Abstract][Full Text] [Related]
12. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
Wassenaar MJ; Dekkers OM; Pereira AM; Wit JM; Smit JW; Biermasz NR; Romijn JA
J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the influencing factors of recombinant human growth hormone effect in the children with Turner syndrome].
Li J; Wu W; Liang Y; Luo XP
Zhonghua Er Ke Za Zhi; 2018 Nov; 56(11):866-870. PubMed ID: 30392213
[No Abstract] [Full Text] [Related]
14. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
[TBL] [Abstract][Full Text] [Related]
15. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome.
Ko JM; Kim JM; Cheon CK; Kim DH; Lee DY; Cheong WY; Kim EY; Park MJ; Yoo HW
Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916
[TBL] [Abstract][Full Text] [Related]
16. GHR and VDR genes do not contribute to the growth hormone (GH) response in GH deficient and Turner syndrome patients.
Alvarez-Nava F; Marcano H; Pardo T; Paoli M; Gunczler P; Soto M; Villaloboss J; Lanes R
J Pediatr Endocrinol Metab; 2010 Aug; 23(8):773-82. PubMed ID: 21073120
[TBL] [Abstract][Full Text] [Related]
17. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency.
Räz B; Janner M; Petkovic V; Lochmatter D; Eblé A; Dattani MT; Hindmarsh PC; Flück CE; Mullis PE
J Clin Endocrinol Metab; 2008 Mar; 93(3):974-80. PubMed ID: 18029459
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment.
Jorge AA; Arnhold IJ
Horm Res; 2009 Apr; 71 Suppl 2():55-63. PubMed ID: 19407498
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to evaluate gene expression profiles in peripheral blood mononuclear cells (PBMCs) from children with GH deficiency and Turner syndrome in response to GH treatment.
Whatmore AJ; Patel L; Clayton PE
Clin Endocrinol (Oxf); 2009 Mar; 70(3):429-34. PubMed ID: 19018778
[TBL] [Abstract][Full Text] [Related]
20. The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
Hellgren G; Glad CA; Jonsson B; Johannsson G; Albertsson-Wikland K
Growth Horm IGF Res; 2015 Jun; 25(3):127-35. PubMed ID: 25742716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
